Skip to main content

Advertisement

SpringerLink
Log in

Natural history of HCV infection

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background

There is much controversy surrounding the natural history of hepatitis C virus (HCV) infection.

Aims

The aim of this review was to review the natural history of HCV infection.

Methods

Published English literature was searched via pubmed and then reviewed.

Results

Approximately, 75–85% of HCV-infected persons will progress to chronic HCV infection. The rate of chronic HCV infection is affected by a person’s age, gender, race, and viral immune response. Once chronic HCV infection develops, there are external and host factors that can increase the risk of progression of liver disease. Progression of chronic HCV infection is not linear in time, probably because many cofactors change the rate of development of fibrosis, cirrhosis, and hepatocellular carcinoma. Factors linked with aggressive disease progression include age at infection, duration of infection, heavy alcohol use, co-infections with HIV or hepatitis B virus, male sex, steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics. However, the relative importance of many and varied factors remains uncertain, and further research efforts should be directed toward design of predictive models for effective risk stratification. Interferon-based therapy, particularly among those achieving a sustained virologic response (SVR), is associated with improved fibrosis and inflammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy.

Conclusions

Despite the progress in understanding the factors affecting the natural history of HCV infection, a great deal remains to be learnt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194(10):1395–1406

    Article  PubMed  CAS  Google Scholar 

  2. Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33(5):559–565

    Article  PubMed  CAS  Google Scholar 

  3. Wright TL, Hsu H, Donegan E, et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med 1991;115(2):111–112

    PubMed  CAS  Google Scholar 

  4. Kanda T, Yokosuka O, Imazeki F, et al. Acute hepatitis C virus infection, 1986–2001: a rare cause of fulminant hepatitis in Chiba, Japan. Hepatogastroenterology 2004;51(56):556–558

    PubMed  Google Scholar 

  5. Amin J, Law MG, Micallef J, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect 2007;135(1):144–150

    Article  PubMed  CAS  Google Scholar 

  6. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001;35(4):531–537

    Article  PubMed  CAS  Google Scholar 

  7. Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in HIV-1 infected individuals. J Gen Virol 2011;92:2227–2236

    Article  PubMed  CAS  Google Scholar 

  8. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284(4):450–456

    Article  PubMed  CAS  Google Scholar 

  9. Bigger CB, Guerra B, Brasky KM, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779–13792

    Article  PubMed  CAS  Google Scholar 

  10. Keller BC, Johnson CL, Erickson AK, et al. Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev 2007;18:535–544

    Article  PubMed  CAS  Google Scholar 

  11. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009;66:733–756

    Article  PubMed  CAS  Google Scholar 

  12. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645–1655

    Article  PubMed  CAS  Google Scholar 

  13. Zeremski M, Hooker G, Shu MA, et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 2011;55:545–552

    Article  PubMed  CAS  Google Scholar 

  14. Romero-Gomez M, Eslam M, Ruiz A, et al. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011;31(4):443–460

    Article  PubMed  CAS  Google Scholar 

  15. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798–801

    Article  PubMed  CAS  Google Scholar 

  16. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134(6):1699–1714

    Article  PubMed  CAS  Google Scholar 

  17. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463–1466

    Article  PubMed  CAS  Google Scholar 

  18. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671–675

    Article  PubMed  CAS  Google Scholar 

  19. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35–S46

    Article  PubMed  Google Scholar 

  20. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418–431

    Article  PubMed  Google Scholar 

  21. Lawson A, Trent Hepatitis C Study Group. A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. J Viral Hepat 2011;18:e270–e277

    Article  PubMed  CAS  Google Scholar 

  22. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75(3):347–354

    Article  PubMed  CAS  Google Scholar 

  23. Kiyosawa K. Trend of liver cirrhosis as precancerous lesions. Hepatol Res 2002;24:40–45

    Article  Google Scholar 

  24. Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32(3):344–355

    Article  PubMed  CAS  Google Scholar 

  25. Bruno S, Crosignani A, Maisonneuve P, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350–1356

    Article  PubMed  CAS  Google Scholar 

  26. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687–1695

    Article  PubMed  CAS  Google Scholar 

  27. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472

    Article  PubMed  CAS  Google Scholar 

  28. Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011;9:71–78

    Article  PubMed  Google Scholar 

  29. Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938–945

    Article  PubMed  Google Scholar 

  30. Hissar SS, Kumar M, Tyagi P, et al. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. J Gastroenterol Hepatol 2009;24(4):581–587

    Article  PubMed  Google Scholar 

  31. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121–124

    Article  PubMed  CAS  Google Scholar 

  32. Poynard T, Ratziu V, Charlotte F, et al. Rate and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730–739

    Article  PubMed  CAS  Google Scholar 

  33. Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology 2007;45:1282–1289

    Article  PubMed  Google Scholar 

  34. Scott JD, McMahon BJ, Bruden D, et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis 2006;42:945–952

    Article  PubMed  CAS  Google Scholar 

  35. Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child–Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006;78:459–465

    Article  PubMed  Google Scholar 

  36. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005;129:2064–2075

    Article  PubMed  CAS  Google Scholar 

  37. Bitetto D, Fabris C, Fornasiere E, et al. IL28B rs12979860 C > T polymorphism affects the evolution of chronic Hepatitis C. Hepatology 2010;52(Suppl):438A

    Google Scholar 

  38. Del Campo JA, Maraver Zamora M, Ramirez-Lorca R, et al. Real LM.IL28B polymorphism predicts sustained virological response in hepatitis C but is not associated with fibrosis or viral load. Hepatology 2010;52(Suppl):748A

    Google Scholar 

  39. Thompson AJ, Clark PJ, Fellay J, et al. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the ideal study. Hepatology 2010;52:2243–2244

    Article  PubMed  Google Scholar 

  40. Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011;54(4):1127–1134

    Article  PubMed  CAS  Google Scholar 

  41. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679–1687

    Article  PubMed  CAS  Google Scholar 

  42. Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120–124

    PubMed  CAS  Google Scholar 

  43. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008;6:69–75

    Article  PubMed  Google Scholar 

  44. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562–569

    Article  PubMed  CAS  Google Scholar 

  45. Freedman ND, Everhart JE, Lindsay KL, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009;50:1360–1369

    Article  PubMed  CAS  Google Scholar 

  46. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51:201–209

    Article  PubMed  CAS  Google Scholar 

  47. Everhart JE, Lok AS, Kim HY, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009;137:549–557

    Article  PubMed  Google Scholar 

  48. Kobayashi M, Tanaka E, Sodayama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotype 1 and 2 hepatitis C viruses. Hepatology 1996;23:669–695

    Article  Google Scholar 

  49. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754–758

    Article  PubMed  CAS  Google Scholar 

  50. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406–412

    Article  PubMed  CAS  Google Scholar 

  51. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655–666

    Article  PubMed  CAS  Google Scholar 

  52. De Nicola S, Aghemo A, Rumi MG, et al. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:964–966

    Article  PubMed  Google Scholar 

  53. Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211–215

    Article  PubMed  CAS  Google Scholar 

  54. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:764–767

    Article  Google Scholar 

  55. Harris HE, Eldridge KP, Harbour S, et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepatol 2007;14:213–220

    Article  PubMed  CAS  Google Scholar 

  56. Nousbaum JB, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995;122:161–168

    PubMed  CAS  Google Scholar 

  57. Hatzakis A, Katsoulidou A, Kaklamani E, et al. Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int J Cancer 1996;68:51–53

    Article  PubMed  CAS  Google Scholar 

  58. Mihm S, Fayyazi A, Hartmann H, et al. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25:735–739

    Article  PubMed  CAS  Google Scholar 

  59. Kamal S, Nasser I. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 2008;47:1371–1383

    Article  PubMed  CAS  Google Scholar 

  60. Antaki N, Craxi A, Kamal SM, et al. The neglected hepatitis C virus genotype 4, 5 and 6: an international consensus report. Liver Int 2010;30:342–355

    Article  PubMed  CAS  Google Scholar 

  61. Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum marker of fibrosis. Hepatology 2006;43:771–779

    Article  PubMed  CAS  Google Scholar 

  62. Seto WK, Lai CL, Fung J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010;53(3):444–448

    Article  PubMed  CAS  Google Scholar 

  63. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334–1337

    Article  PubMed  CAS  Google Scholar 

  64. Lambrecht RW, Sterling RK, Naishadham D, et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011;140:1490–1500

    Article  PubMed  CAS  Google Scholar 

  65. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33:704–707

    Article  PubMed  Google Scholar 

  66. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330–337

    PubMed  CAS  Google Scholar 

  67. Kuzushita N, Hayashi N, Katayama K, et al. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol 1996;48:1–7

    Article  PubMed  CAS  Google Scholar 

  68. Silini E, Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285–290

    PubMed  CAS  Google Scholar 

  69. Prati D, Capelli C, Zanella A, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996;110:178–183

    Article  PubMed  CAS  Google Scholar 

  70. Alberti A, Noventa F, Benvegnù L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002;137:961–964

    PubMed  Google Scholar 

  71. Shindo M, Arai K, Sokawa Y, et al. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995;22:418–425

    PubMed  CAS  Google Scholar 

  72. Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006;4:645–652

    Article  PubMed  CAS  Google Scholar 

  73. Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79(4):688–694

    Article  PubMed  CAS  Google Scholar 

  74. Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136–146

    Article  PubMed  CAS  Google Scholar 

  75. Bonis PA, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol 1999;94:1605–1612

    Article  PubMed  CAS  Google Scholar 

  76. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31:513–520

    Article  PubMed  CAS  Google Scholar 

  77. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132(7):517–524

    PubMed  CAS  Google Scholar 

  78. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123(2):483–491

    Article  PubMed  CAS  Google Scholar 

  79. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004;53(3):425–430

    Article  PubMed  CAS  Google Scholar 

  80. Camm`a C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39(2):333–342

    Article  CAS  Google Scholar 

  81. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Alimentary Pharmacol Ther 2008;27(7):542–551

    Article  CAS  Google Scholar 

  82. Okanoue T, Itoh Y, Kirishima T, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res 2002;23:62–77

    Article  PubMed  CAS  Google Scholar 

  83. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131(3):174–181

    PubMed  CAS  Google Scholar 

  84. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142(2):105–114

    PubMed  CAS  Google Scholar 

  85. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52(5):652–657

    Article  PubMed  CAS  Google Scholar 

  86. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010;8(2):192–199

    Article  PubMed  Google Scholar 

  87. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51(6):2069–2076

    Article  PubMed  CAS  Google Scholar 

  88. Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepatol 2004;11(2):148–156

    Article  PubMed  CAS  Google Scholar 

  89. Deuffic-Burban S, Deltenre P, Louvet A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008;49(2):175–183

    Article  PubMed  Google Scholar 

  90. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross-sectional and longitudinal study. Gut 2003;52:574–579

    Article  PubMed  CAS  Google Scholar 

  91. Kim WR, Poterucha JJ, Benson JT, et al. The impact of competing risks on the observed rate of chronic hepatitis C progression. Gastroenterology 2004;127:749–755

    Article  PubMed  Google Scholar 

  92. Poynard T, Ratziu V, Kim N, et al. Age and gender will survive to competing risks as fibrosis factors. Gastroenterology 2005;128:519–520

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatology, Institute of Liver and Biliary Sciences, D1 Vasant Kunj, New Delhi, India

    Shiv K. Sarin & Manoj Kumar

Authors
  1. Shiv K. Sarin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manoj Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiv K. Sarin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarin, S.K., Kumar, M. Natural history of HCV infection. Hepatol Int 6, 684–695 (2012). https://doi.org/10.1007/s12072-012-9355-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-012-9355-6

Keywords

Search

Navigation